Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases. Issue 6 (December 2021)

• Record Type: Journal Article
• Authors: Canino, Fabio; Pugliese, Giuseppe; Baldessari, Cinzia; Greco, Stefano; Depenni, Roberta; Dominici, Massimo
• Is Part Of: Tumori. Volume 107:Issue 6(2021)
• Page Start: NP123
• Page End: NP126
• Publication Date: 2021-12
• Subjects: Immunotherapy -- immune-related adverse events -- cemiplimab -- nivolumab -- myasthenia gravis; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916211040559
• Languages: English
• ISSNs: 0300-8916

Abstract

Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis observed at the Modena Cancer Center in two elderly patients treated with two anti-PD-1 monoclonal antibodies: cemiplimab and nivolumab.